Literature DB >> 7110299

Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.

J Pedersen-Bjergaard, S O Larsen.   

Abstract

During the period from 1970 to 1981, 391 nonselected patients with Hodgkin's disease were staged and treated with chemotherapy or radiotherapy or both at the Finsen Institute, Copenhagen. Secondary acute nonlymphocytic leukemia or its earlier stages--preleukemia or an acute myeloproliferative syndrome with cytopenia and specific cytogenetic abnormalities of the bone marrow--were observed in 17 patients. A Kaplan-Meier estimate of the cumulative probability of leukemic complications was 3.9 +/- 1.3 per cent (mean +/- S.E.M.) five years after the start of treatment, and 9.9 +/- 2.9 per cent at nine years. All 17 cases of leukemic complications occurred among the 312 patients treated with chemotherapy or combined-modality therapy, whereas no case was observed among 79 patients treated exclusively with radiotherapy (P = 0.003). A significantly increased risk of leukemic complications was observed in chemotherapy-treated patients 40 years old or older (P = 0.001). Despite the observed relatively high risk of secondary leukemia, the rate of death from progressive Hodgkin's disease, nonleukemic complications, and unrelated causes still far exceeds the rate of leukemia-related deaths in these patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7110299     DOI: 10.1056/NEJM198210143071601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  28 in total

1.  Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.

Authors:  S Devereux; T G Selassie; G Vaughan Hudson; B Vaughan Hudson; D C Linch
Journal:  BMJ       Date:  1990-11-10

Review 2.  Leukaemia and cancer chemotherapy.

Authors:  C J Williams
Journal:  BMJ       Date:  1990-07-14

3.  Transforming genes and chromosome aberrations in therapy-related leukemia and myelodysplastic syndrome.

Authors:  K Inokuchi; N Amuro; M Futaki; K Dan; T Shinohara; S Kuriya; T Okazaki; T Nomura
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

4.  Acute leukemia in a patient cured of diffuse histiocytic lymphoma.

Authors:  J P Dutcher; P H Wiernik
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 5.  Current management of Hodgkin's disease.

Authors:  B C Behrens; R C Young; V T DeVita
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

6.  Therapy-related acute nonlymphocytic leukemia: clinical aspects.

Authors:  J Pedersen-Bjergaard
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

7.  Lung cancer following therapy for Hodgkin's disease.

Authors:  L Oliphant; R G McFadden
Journal:  Can Med Assoc J       Date:  1985-03-01       Impact factor: 8.262

8.  Alcohol use is not a significant contributor to myelodysplastic syndromes.

Authors:  Elizabeth A Duffy; Phuong L Nguyen; Adina Cioc; Erica Warlick; Michelle A Roesler; Jenny N Poynter
Journal:  Cancer Causes Control       Date:  2020-04-13       Impact factor: 2.506

Review 9.  [Individualized management and therapy of myelodysplastic syndromes].

Authors:  Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  Patients with multiple primary gastric cancers tend to develop second primaries in organs other than the stomach.

Authors:  N Kaibara; M Maeta; M Ikeguchi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.